ViroPharma Incorporated (NASDAQ: VPHM), a multinational biotechnology company, is focused on developing and commercializing innovative products that target unmet medical needs. The company is currently dedicating their efforts to developing these products for physician specialists that support patients with serious diseases caused by CMV, C. difficile, and hereditary angioedema. Maribavir, VioPharma’s lead clinical compound, is an orally-administered antiviral Phase 3 drug designed to prevent cytomegalovirus (CMV) disease in transplant patients. For further information, visit the Company’s web site at www.viropharma.com.
- 18 years ago
QualityStocks
ViroPharma Incorporated (NASDAQ: VPHM)
Tags Rodman & Renshaw
Related Post
-
Greenland Mines Ltd. (NASDAQ: GRML) Advances World-Class Palladium Deposit with Major Resource Upgrade
The combination of a structurally concentrated supply base, rising geopolitical risk from the dominant Russian…
-
Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market
Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Is Building a Modern Public Safety Platform by Integrating Tools, Training and Policy
Wrap Technologies treats non-lethal response as a system rather than a single device, integrating tools,…